237 related articles for article (PubMed ID: 30344420)
1. Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.
Schaffner D; Lazaro A; Deibert P; Hasselblatt P; Stoll P; Fauth L; Baumstark MW; Merfort I; Schmitt-Graeff A; Kreisel W
World J Gastroenterol; 2018 Oct; 24(38):4356-4368. PubMed ID: 30344420
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.
Kreisel W; Schaffner D; Lazaro A; Trebicka J; Merfort I; Schmitt-Graeff A; Deibert P
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872119
[TBL] [Abstract][Full Text] [Related]
3. Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats.
Brusilovskaya K; Königshofer P; Lampach D; Szodl A; Supper P; Bauer D; Beer A; Stift J; Timelthaler G; Oberhuber G; Podesser BK; Seif M; Zinober K; Rohr-Udilova N; Trauner M; Reiberger T; Schwabl P
United European Gastroenterol J; 2020 Dec; 8(10):1174-1185. PubMed ID: 32878579
[TBL] [Abstract][Full Text] [Related]
4. Soluble Guanylyl Cyclase Activator BI 685509 Reduces Portal Hypertension and Portosystemic Shunting in a Rat Thioacetamide-Induced Cirrhosis Model.
Jones AK; Chen H; Ng KJ; Villalona J; McHugh M; Zeveleva S; Wilks J; Brilisauer K; Bretschneider T; Qian HS; Fryer RM
J Pharmacol Exp Ther; 2023 Jul; 386(1):70-79. PubMed ID: 37230799
[TBL] [Abstract][Full Text] [Related]
5. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats.
Xie G; Wang X; Wang L; Wang L; Atkinson RD; Kanel GC; Gaarde WA; Deleve LD
Gastroenterology; 2012 Apr; 142(4):918-927.e6. PubMed ID: 22178212
[TBL] [Abstract][Full Text] [Related]
6. Tetrandrine ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Wang H; Chen X
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(4):385-8, 395. PubMed ID: 15587405
[TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil ameliorates NOSTRIN-NO dependent portal hypertension in cirrhosis and ACLF.
Vairappan B; Wright G; M S; Ravikumar TS
Eur J Pharmacol; 2023 Nov; 958():176010. PubMed ID: 37634841
[TBL] [Abstract][Full Text] [Related]
8. Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats.
Lafoz E; Campreciós G; García-Calderó H; Anton A; Vilaseca M; Ruart M; Guasch E; Garrabou G; Delgado TC; Martínez-Chantar ML; García-Martínez R; Gracia-Sancho J; Hernández-Gea V; García-Pagán JC
Am J Physiol Gastrointest Liver Physiol; 2021 Dec; 321(6):G603-G616. PubMed ID: 34585619
[TBL] [Abstract][Full Text] [Related]
9. Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: a preliminary study.
Wei L; Yang J; Wang M; Xu SN; Liang HM; Zhou Q
Int J Mol Med; 2014 Nov; 34(5):1257-67. PubMed ID: 25174394
[TBL] [Abstract][Full Text] [Related]
10. Effect of sildenafil citrate on interleukin-1beta-induced nitric oxide synthesis and iNOS expression in SW982 cells.
Kim KO; Park SY; Han CW; Chung HK; Yoo DH; Han JS
Exp Mol Med; 2008 Jun; 40(3):286-93. PubMed ID: 18587266
[TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease.
Lee DI; Zhu G; Sasaki T; Cho GS; Hamdani N; Holewinski R; Jo SH; Danner T; Zhang M; Rainer PP; Bedja D; Kirk JA; Ranek MJ; Dostmann WR; Kwon C; Margulies KB; Van Eyk JE; Paulus WJ; Takimoto E; Kass DA
Nature; 2015 Mar; 519(7544):472-6. PubMed ID: 25799991
[TBL] [Abstract][Full Text] [Related]
12. Homogeneous single-label cGMP detection platform for the functional study of nitric oxide-sensitive (soluble) guanylyl cyclases and cGMP-specific phosphodiesterases.
Kopra K; Sharina I; Martin E; Härmä H
Sci Rep; 2020 Oct; 10(1):17469. PubMed ID: 33060787
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs.
Ramseyer VD; Ortiz PA; Carretero OA; Garvin JL
Am J Physiol Renal Physiol; 2016 Apr; 310(8):F748-F754. PubMed ID: 26887831
[TBL] [Abstract][Full Text] [Related]
14. Effect of ginger, Paullinia cupana, muira puama and l- citrulline, singly or in combination, on modulation of the inducible nitric oxide- NO-cGMP pathway in rat penile smooth muscle cells.
Ferrini MG; Garcia E; Abraham A; Artaza JN; Nguyen S; Rajfer J
Nitric Oxide; 2018 Jun; 76():81-86. PubMed ID: 29551532
[TBL] [Abstract][Full Text] [Related]
15. The nitric oxide-cyclic guanosine monophosphate pathway inhibits the bladder ATP release in response to a physiological or pathological stimulus.
Okuyama E; Kawatani M; Hashimoto J; Tanimoto K; Hashimoto M; Matsumoto-Miyai K
Physiol Rep; 2021 Jul; 9(14):e14938. PubMed ID: 34288526
[TBL] [Abstract][Full Text] [Related]
16. Liver-targeted nanoparticles delivering nitric oxide reduce portal hypertension in cirrhotic rats.
Perramón M; Navalón-López M; Fernández-Varo G; Moreno-Lanceta A; García-Pérez R; Faneca J; López-Moya M; Fornaguera C; García-Villoria J; Morales-Ruiz M; Melgar-Lesmes P; Borrós S; Jiménez W
Biomed Pharmacother; 2024 Feb; 171():116143. PubMed ID: 38219387
[TBL] [Abstract][Full Text] [Related]
17. Partial portal vein ligation plus thioacetamide: a method to obtain a new model of cirrhosis and chronic portal hypertension in the rat.
Méndez-López M; Méndez M; Sánchez-Patán F; Casado I; Aller MA; López L; Corcuera MT; Alonso MJ; Nava MP; Arias J; Arias JL
J Gastrointest Surg; 2007 Feb; 11(2):187-94. PubMed ID: 17390171
[TBL] [Abstract][Full Text] [Related]
18. Exploring the Multifaceted Potential of Sildenafil in Medicine.
Pușcașu C; Zanfirescu A; Negreș S; Șeremet OC
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138293
[TBL] [Abstract][Full Text] [Related]
19. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.
Yang Y; Nemoto EM; Harvey SA; Subbotin VM; Gandhi CR
Gut; 2004 Jun; 53(6):877-83. PubMed ID: 15138217
[TBL] [Abstract][Full Text] [Related]
20. A 2-week treatment with 5-azacytidine improved the hypercontractility state in prostate from obese mice: Role of the nitric oxide-cyclic guanosine monophosphate signalling pathway.
Ghezzi AC; Passos GR; de Oliveira MG; Oliveira AL; Assis-Mendonça GR; de Mello GC; Antunes E; Monica FZ
Clin Exp Pharmacol Physiol; 2024 Apr; 51(4):e13851. PubMed ID: 38452757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
